Gitnux/Report 2026

Cell and Gene Therapy Industry Statistics

The global cell and gene therapy market is estimated at $16.45 billion in 2026, explore the figures behind growth, companies and trends.
19Statistics
24Sources
3Sections
1Visuals
15mRead
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 44 days

01 Industry overview

The cell and gene therapy industry at a glance

The global cell and gene therapy market is estimated at $16.45 billion in 2026, with North America dominant and clinical development continuing to expand across oncology, rare diseases and genetic disorders.

$16.45B[10]
Global market size, 2026
31.1%[10]
Forecast CAGR, 2026–2034
52.58%[10]
North America market share, 2025
2,130[6]
Regional clinical trials, Q4 2025
Market size
The global cell and gene therapy market was valued at $12.21 billion in 2025 and is estimated at $16.45 billion in 2026. A separate market estimate places the 2025 cell and gene therapy CDMO segment at $5.2 billion, indicating the growing importance of outsourced manufacturing within the broader industry.[10][1]
Forecast & CAGR
The overall cell and gene therapy market is forecast to reach $143.55 billion by 2034, representing a 31.1% CAGR from 2026 to 2034. The CDMO segment is projected to grow from $6.2 billion in 2026 to $27.1 billion in 2033, at a 23.4% CAGR.[10][1]
Market share & regions
North America accounted for 52.58% of the global cell and gene therapy market in 2025. In the CDMO segment, North America held a 40.8% revenue share in 2025, while Asia-Pacific was identified as the fastest-growing region through 2033.[10][1]
Segmentation
The market is segmented into cell therapy and gene therapy. Cell therapy includes CAR-T, TCR-T and natural-killer-cell approaches, while gene therapy is segmented by viral versus non-viral vectors and by indications such as genetic diseases, ophthalmology and hematology; in the CDMO market, preclinical work represented 65.0% of 2025 revenue and oncology was the leading indication.[10][1]
Key players & concentration
The industry includes large pharmaceutical companies such as Vertex Pharmaceuticals, Novartis and Bristol Myers Squibb alongside specialist developers and manufacturing providers. ARM counted 1,856 developers globally in Q4 2025, including 703 in North America, 685 in Europe and 396 in Asia-Pacific, indicating a fragmented developer base rather than a narrowly concentrated field.[10][6]
Pricing
Commercial cell and gene therapies often have multimillion-dollar list prices: Lenmeldy is listed at $4.25 million, while Zolgensma is priced near $2.1 million. Casgevy and Lyfgenia are also priced in the multimillion-dollar range, increasing the importance of outcomes-based reimbursement and payer negotiation.[11][12]
Trends, drivers & challenges
Clinical development remains the main growth engine: ARM reported 2,130 regional clinical trials and $3.2 billion of regional investment in Q4 2025, while Asia-Pacific hosted 990 trials, North America 916 and Europe 337. Key challenges include complex manufacturing, patient-specific logistics, high treatment costs and the need for long-term safety monitoring.[6][13]
Consumer behavior & competition
Competition is shifting from pipeline breadth toward clinical differentiation, manufacturing scalability and access to specialized treatment centers. The 2025 pipeline was concentrated in early development, with genetically modified cell therapies representing 53% of clinical trials and 46% of approved products in the ISCT review.[14][6]
M&A
Cell and gene therapy dealmaking remained substantial in 2026: Gilead’s acquisition of Arcellx involved $7.8 billion, while Eli Lilly’s acquisition of Kelonia Therapeutics involved $3.25 billion upfront. Total 2026 M&A upfront consideration and commitments reached $14.8 billion through the first three quarters, already above the comparable $12.0 billion 2025 series.[14]
Regulation
The FDA’s approved-product list included more than 40 licensed cellular and gene therapy products by late 2026, spanning CAR-T therapies, genome-edited products, viral-vector therapies and tissue-engineered products. Globally, 17 products received approval in the first half of 2026, with gene therapies accounting for 47% of those approvals.[13][14]
Latest news
The latest regulatory activity includes the FDA’s July 1, 2026 approval expanding Casgevy to children aged 2 years and older with sickle cell disease. In the first half of 2026, ISCT recorded 17 global product approvals, while the active clinical-trial pipeline remained dominated by Phase I and Phase II studies, which represented 95% of the global pipeline.[13][14]

02 Ranking

Top 10 Companies in the Cell And Gene Therapy Industry

The leading companies in the cell and gene therapy industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 18, 2026 · Next review December 18, 2026

Verdict

Vertex Pharmaceuticals stands out for CRISPR-based gene-edited cell therapy because it commercializes Casgevy with CRISPR Therapeutics, while Novartis focuses on CAR-T and gene therapy since it reports commercial sales for Kymriah CAR-T and Zolgensma gene therapy.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in gene-edited cell therapy

    Vertex Pharmaceuticals

    US

    Ranked #1 · 9.5 · Gene-edited cell therapy

    Why we picked it: Casgevy is Vertex’s commercial CRISPR-based gene-edited cell therapy, and the firm reports 34.8% operating margin.

  2. Leader in CAR-T cell therapy

    Novartis

    CH

    Ranked #2 · 9.1 · CAR-T cell therapy

    Why we picked it: Novartis reports commercial sales for Kymriah CAR-T and Zolgensma gene therapy, with an operating margin of 32.4%.

  3. Leader in topical gene therapy

    Krystal Biotech

    US

    Ranked #3 · 9.1 · Topical gene therapy

    Why we picked it: Krystal Biotech’s VYJUVEK posted $389.1 million in 2025 revenue, alongside a 41.45% operating margin.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the cell and gene therapy industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Vertex Pharmaceuticals

Gene-edited cell therapy · US

9.5
2

Novartis

CAR-T cell therapy · CH

9.1
3

Krystal Biotech

Topical gene therapy · US

9.1
4

Legend Biotech

CAR-T cell therapy · US

9.0
5

BioMarin

Genetic-disease therapies · US

8.9
6

Bristol Myers Squibb

Breyanzi and Abecma CAR-T, global · US

8.9
7

Ferring Pharmaceuticals

Adstiladrin gene therapy, global · CH

8.9
8

Gilead Sciences

Kite CAR-T and cell therapies, global · US

8.9
9

Iovance Biotherapeutics

TIL cell therapy, United States · US

8.7
10

Genetix Biotherapeutics

Gene-addition cell therapies, United States · US

8.7

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 18, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 19). Top 10 companies in the cell and gene therapy industry. In Cell And Gene Therapy Industry Statistics. Gitnux. https://gitnux.org/cell-and-gene-therapy-industry-statistics/#top-companies

report visual · Projection

Global cell and gene therapy funding

Global cell and gene therapy funding fell from $22.7B in 2021 to $11.1B in 2025.

$22.7B
Start
-16.38%
CAGR · 4y
$11.1B
Projected
20212025
source-verifiedinvestor.chemometec.com2025

04 Statistics

Market Intelligence

Market-intelligence figures quantify the outsourced buildout. CDMO services were estimated at $6.24 billion globally in 2024 and are projected to reach $27.1 billion by 2033.

Market size and service revenue in the cell and gene therapy industry

  • $1.62 billion was the estimated U.S. cell and gene therapy CDMO services market in 2024, covering preclinical and clinical contract development and manufacturing services.[1]
  • $6.24 billion was the estimated global cell and gene therapy CDMO services market in 2024, covering contract development and manufacturing services for cell and gene therapies.[2]
  • $5.3 billion was the estimated global cell and gene therapy contract research organization services market in 2024, covering CRO services for cell and gene therapy development.[1]

Growth forecasts for the cell and gene therapy industry

  • 10.0% was the projected compound annual growth rate for the global cell and gene therapy CRO services market from 2024 to 2033, reaching $11.3 billion in 2033.[1]
  • 23.4% was the projected compound annual growth rate for the global cell and gene therapy CDMO services market from 2026 to 2033, reaching $27.1 billion in 2033.[1]
  • 27.9% was the projected compound annual growth rate for the global cell and gene therapy CDMO services market from 2025 to 2034, reaching $73.11 billion in 2034.[2]

Demand shifts in the cell and gene therapy industry

  • More than 30% of advanced therapy developers were actively considering partnerships for growth in 2024, based on Deloitte’s survey of 376 industry stakeholders.[3]
  • The share of respondents expecting to outsource 91–100% of cell and gene manufacturing fell to 14% for future projects from 21% currently in BioPlan’s survey, indicating a shift toward partial outsourcing.[4]
  • 24% of cell and gene therapy outsourcing decision-makers reported having no manufacturing capacity and outsourcing 100% of manufacturing, based on ISR’s survey of 100 respondents.[5]

Regional breakdown of the cell and gene therapy industry

  • 1,262 developers were recorded in North America, 1,036 in Asia-Pacific and 587 in Europe in Q3 2024; totals include additional regions.[6]
  • 1,036 cell and gene therapy clinical trials were recorded in North America, 987 in Asia-Pacific and 363 in Europe in Q3 2024; totals include additional regions.[6]
  • Q3 2024 cell and gene therapy investment was $1.6 billion in North America, $1.1 billion in Asia-Pacific and $0.3 billion in Europe; totals include additional regions.[6]

05 Statistics

Delivery & Operations

Delivery and operations show where manufacturing capacity sits in the surveyed UK network. In 2024, 32 MHRA-licensed cell and gene therapy sites were recorded.

Delivery capacity and installed base in the cell and gene therapy industry

  • 32 UK MHRA-licensed cell and gene therapy manufacturing sites were recorded in 2024, covering the sector’s surveyed GMP manufacturing infrastructure.[7]
  • 10 cleanrooms were available at NHS Blood and Transplant’s Clinical Biotechnology Centre in Filton, UK, operational from 2023 for cell and gene therapy manufacturing.[8]
  • 940 m² of facility space was available at NHS Blood and Transplant’s Clinical Biotechnology Centre in Filton, UK, operational from 2023 for cell and gene therapy manufacturing.[8]
  • 183 cleanrooms were available across UK cell and gene therapy manufacturing sites in 2024.[7]

06 Statistics

Pricing

Pricing data highlights high per-lot testing costs and assessment budgets. Complex release and biosafety testing exceeded $80,000 per lot in 2025.

Fees and price levels in the cell and gene therapy industry

  • $881–$1,824 per sample was the 2025 global price range for biologics-CDMO quality-control testing; the study identifies complex cell-and-gene-therapy release and biosafety testing as capable of exceeding $80,000 per lot.[1]
  • More than $80,000 per lot was charged for complex cell-and-gene-therapy release and biosafety testing in 2025, according to a global biologics-CDMO pricing study.[1]
  • $50,000–$190,000 per project was the 2024–2025 price range for platform-feasibility and manufacturability assessments by advanced-therapy CDMOs, varying with scale; the source covers global gene-therapy service providers.[9]

Key questions about the cell and gene therapy industry

How large is the cell and gene therapy market in 2026?
The global cell and gene therapy market is estimated at $16.45 billion in 2026, up from $12.21 billion in 2025.
What growth rate should we use for 2026–2034?
The market forecast shows a 31.1% CAGR from 2026 to 2034, reaching $143.55 billion by 2034.
Which companies lead the cell and gene therapy industry?
Vertex Pharmaceuticals stands out for CRISPR-based gene-edited cell therapy because it commercializes Casgevy with CRISPR Therapeutics, while Novartis focuses on CAR-T and gene therapy since it reports commercial sales for Kymriah CAR-T and Zolgensma gene therapy.
How are technology and pipeline mixes shifting?
Genetically modified cells represented 53% of clinical trials and 46% of approved products in the ISCT review, while the pipeline remained dominated by Phase I and Phase II studies, which represented 95% of the global pipeline.
How is the developer base structured across regions?
ARM counted 1,856 developers globally in Q4 2025, with 703 in North America, 685 in Europe, and 396 in Asia-Pacific.
What does outsourced capacity demand look like for CDMOs?
The CDMO segment is projected to grow from $6.2 billion in 2026 to $27.1 billion in 2033 at a 23.4% CAGR, and BioPlan’s survey shows expectations to outsource 91–100% fell to 14% from 21% currently.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 19). Cell And Gene Therapy Industry Statistics. Gitnux. https://gitnux.org/cell-and-gene-therapy-industry-statistics
MLA
Samuel Norberg. "Cell And Gene Therapy Industry Statistics." Gitnux, 19 Nov 2026, https://gitnux.org/cell-and-gene-therapy-industry-statistics.
Chicago
Samuel Norberg. 2026. "Cell And Gene Therapy Industry Statistics." Gitnux. https://gitnux.org/cell-and-gene-therapy-industry-statistics.